An FDA advisory panel recommended against including a "black box" warning about the risk of suicidal behavior on the packaging of anti-seizure medications. Panel members voted in favor of providing medical practitioners with a medication guide explaining such risks. A Pfizer official said the labeling for Lyrica and Neurontin correctly shows their risk and benefit profiles, while a GlaxoSmithKline executive said the company thinks Lamictal's label should carry more suicide-risk data.

Related Summaries